Choline Fenofibrate

• Description:

  Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect[1].

• Product Name Alternative:

  ABT-335

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  COX; PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Choline-Fenofibrate.html

• Purity:

  99.86

• Solubility:

  DMSO : 20 mg/mL (ultrasonic) |Ethanol : 33.33 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(OC(C)(C([O-])=O)C)C=C1)C2=CC=C(Cl)C=C2.C[N+](C)(CCO)C

• Molecular Formula:

  C22H28ClNO5

• Molecular Weight:

  421.91

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Xudan Wei, et al. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31 (4) .

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [856676-23-8]